R21/Matrix-M1

BIOLOGICAL3 trials

Sponsors

University of Oxford, Oxford University

Conditions

Healthy Women of Child Bearing PotentialMalaria

Phase 1

A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant

CompletedNCT02925403

University of OxfordMalaria

Start: 2016-08-26End: 2017-02-15Updated: 2019-11-06

Phase 2

Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali

Active, not recruitingNCT06080243

University of OxfordHealthy Women of Child Bearing Potential

Start: 2025-03-19End: 2027-12-31Target: 330Updated: 2026-02-23

Unknown Phase

A Study to assess the Safety and Immunogenicity of the MAlaria Vaccine, R1, With Matrix-M1 Adjuvant

Active, not recruitingPACTR201610001813366

Oxford UniversityMalaria

Start: 2016-08-15Target: 24Updated: 2026-09-14

Related Papers

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

2025-01-104 citations